Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30336712 | 0.99 | NTRK1 (0.55) | NTRK1NR3C2 | |
| SCHEMBL18680207 | 0.89 | NTRK1 (0.59) | NTRK1 | |
| SCHEMBL18685587 | 0.89 | NTRK1 (0.56) | NTRK1 | |
| SCHEMBL29794762 | 0.89 | MEN1 (0.52) | NTRK1 | |
| SCHEMBL21164987 | 0.89 | NTRK1 (0.58) | NTRK1 | |
| SCHEMBL22415839 | 0.88 | NTRK1 (0.45) | NTRK1 | |
| SCHEMBL18685588 | 0.88 | NTRK1 (0.55) | NTRK1 | |
| SCHEMBL22415908 | 0.87 | NTRK1 (0.51) | NTRK1 | |
| SCHEMBL22415925 | 0.87 | NTRK1 (0.48) | NTRK1 | |
| SCHEMBL22415854 | 0.84 | NTRK1 (0.53) | NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117281803-A | Spray-dried dispersions and formulations | 罗索肿瘤学公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-109970614-B | Compounds as TRKA kinase inhibitors and uses thereof | 阵列生物制药公司（US） | 2023-01-13 | — | — | CN | disclosed |
| CN-111615514-B | Substituted pyrazolo [4,3-C ] pyridine compounds as RET kinase inhibitors | 奥瑞生物药品公司 | 2022-10-11 | — | — | CN | disclosed |
| EP-3412663-B1 | NITROGEN-CONTAINING HETEROCYCLE AND CARBOCYCLE DERIVATIVES HAVING TRKA INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2022-09-07 | — | — | EP | disclosed |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2021-01-12 | — | — | US | disclosed |
| EP-3409670-B1 | N-PYRROLIDINYL, N'-PYRAZOLYL- UREA COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3564236-A1 | PROCESS FOR PREPARING 4-SUBSTITUTED-1-(2-METHOXYETHYL)PYRROLIDIN-3-AMINE DERIVATIVES | Array Biopharma, Inc. (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20190270749-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC. (US) | 2019-09-05 | — | — | US | disclosed |
| US-10351575-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2019-07-16 | — | — | US | disclosed |
| EP-3154959-B1 | 1-((3S,4R)-4-(3-FLUOROPHENYL)-1-(2-METHOXYETHYL)PYRROLIDIN-3-YL)-3-(4-METHYL-3-(2-METHYLPYRIMIDIN-5-YL)-1-PHENYL-1H-PYRAZOL-5-YL)UREA AS A TRKA KINASE INHIBITOR | ARRAY BIOPHARMA INC (US) | 2019-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270749-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | TK1, UACA, TDP1 | NTRK1 79/4885NR3C2 4006/4885 |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | NTRK1 79/4885NR3C2 4006/4885 |
| US-10351575-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | NTRK1 79/4885NR3C2 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.